Embla Medical hf (LTS:0FIW) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0FIW Embla Medical hf LTS:0FIW
80 GF Score
Price kr28.70
GF Value kr33.82
Valuation Modestly Undervalued
View Full Analysis

What is Embla Medical hf FFO per Share?

FFO per Share only applies to REITs.

LTS:0FIW
80GF Score
Embla Medical hf LTS:0FIW
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Embla Medical hf (LTS:0FIW) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of kr28.70 is trading 15.1% below its estimated GF Value™ of kr33.82. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for LTS:0FIW:

  • FFO per Share:
  • GF Value™: kr33.82 vs. price of kr28.70 (15.1% below fair value)
  • GF Score™: 80/100

No single metric tells the full story. See the LTS:0FIW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Other Exchanges EMBLA:Denmark5IQ:Germany
Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
80GF Score

Get the complete analysis for LTS:0FIW

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr28.70
Price
kr33.82
GF Value